Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Pulmonary Drug Delivery Devices Market Research Report 2019-2025

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Pulmonary Drug Delivery Devices Industry
  • 1.7 COVID-19 Impact: Pulmonary Drug Delivery Devices Market Trends

    • 2 Global Pulmonary Drug Delivery Devices Quarterly Market Size Analysis

    • 2.1 Pulmonary Drug Delivery Devices Business Impact Assessment - COVID-19
      • 2.1.1 Global Pulmonary Drug Delivery Devices Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Pulmonary Drug Delivery Devices Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Pulmonary Drug Delivery Devices Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Pulmonary Drug Delivery Devices Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Pulmonary Drug Delivery Devices Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Pulmonary Drug Delivery Devices Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Pulmonary Drug Delivery Devices Market
    • 3.5 Key Manufacturers Pulmonary Drug Delivery Devices Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Pulmonary Drug Delivery Devices Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Dry Powder Inhaler
      • 1.4.2 Metered Dose Inhaler
      • 1.4.3 Nebulizer
    • 4.2 By Type, Global Pulmonary Drug Delivery Devices Market Size, 2019-2021
      • 4.2.1 By Type, Global Pulmonary Drug Delivery Devices Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Pulmonary Drug Delivery Devices Price, 2020-2021

    5 Impact of Covid-19 on Pulmonary Drug Delivery Devices Segments, By Application

    • 5.1 Overview
      • 5.5.1 Asthma
      • 5.5.2 COPD
      • 5.5.3 Cystic Fibrosis
      • 5.5.4 Other
    • 5.2 By Application, Global Pulmonary Drug Delivery Devices Market Size, 2019-2021
      • 5.2.1 By Application, Global Pulmonary Drug Delivery Devices Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Pulmonary Drug Delivery Devices Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Boehringer Ingelheim GmbH
      • 7.1.1 Boehringer Ingelheim GmbH Business Overview
      • 7.1.2 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.1.3 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Product Introduction
      • 7.1.4 Boehringer Ingelheim GmbH Response to COVID-19 and Related Developments
    • 7.2 Novartis AG
      • 7.2.1 Novartis AG Business Overview
      • 7.2.2 Novartis AG Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.2.3 Novartis AG Pulmonary Drug Delivery Devices Product Introduction
      • 7.2.4 Novartis AG Response to COVID-19 and Related Developments
    • 7.3 GlaxoSmithKline
      • 7.3.1 GlaxoSmithKline Business Overview
      • 7.3.2 GlaxoSmithKline Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.3.3 GlaxoSmithKline Pulmonary Drug Delivery Devices Product Introduction
      • 7.3.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.4 AstraZeneca
      • 7.4.1 AstraZeneca Business Overview
      • 7.4.2 AstraZeneca Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.4.3 AstraZeneca Pulmonary Drug Delivery Devices Product Introduction
      • 7.4.4 AstraZeneca Response to COVID-19 and Related Developments
    • 7.5 Teva Pharmaceutical Industries
      • 7.5.1 Teva Pharmaceutical Industries Business Overview
      • 7.5.2 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.5.3 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Product Introduction
      • 7.5.4 Teva Pharmaceutical Industries Response to COVID-19 and Related Developments
    • 7.6 Merck
      • 7.6.1 Merck Business Overview
      • 7.6.2 Merck Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.6.3 Merck Pulmonary Drug Delivery Devices Product Introduction
      • 7.6.4 Merck Response to COVID-19 and Related Developments
    • 7.7 MannKind
      • 7.7.1 MannKind Business Overview
      • 7.7.2 MannKind Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.7.3 MannKind Pulmonary Drug Delivery Devices Product Introduction
      • 7.7.4 MannKind Response to COVID-19 and Related Developments
    • 7.8 Bristol-Myers Squibb
      • 7.8.1 Bristol-Myers Squibb Business Overview
      • 7.8.2 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.8.3 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Product Introduction
      • 7.8.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.9 Mylan N.V
      • 7.9.1 Mylan N.V Business Overview
      • 7.9.2 Mylan N.V Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.9.3 Mylan N.V Pulmonary Drug Delivery Devices Product Introduction
      • 7.9.4 Mylan N.V Response to COVID-19 and Related Developments
    • 7.10 Omron Corp
      • 7.10.1 Omron Corp Business Overview
      • 7.10.2 Omron Corp Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.10.3 Omron Corp Pulmonary Drug Delivery Devices Product Introduction
      • 7.10.4 Omron Corp Response to COVID-19 and Related Developments
    • 7.11 F. Hoffmann-La Roche
      • 7.11.1 F. Hoffmann-La Roche Business Overview
      • 7.11.2 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.11.3 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Product Introduction
      • 7.11.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments
    • 7.12 3M Healthcare
      • 7.12.1 3M Healthcare Business Overview
      • 7.12.2 3M Healthcare Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.12.3 3M Healthcare Pulmonary Drug Delivery Devices Product Introduction
      • 7.12.4 3M Healthcare Response to COVID-19 and Related Developments
    • 7.13 Sunovion Pharmaceuticals
      • 7.13.1 Sunovion Pharmaceuticals Business Overview
      • 7.13.2 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.13.3 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Product Introduction
      • 7.13.4 Sunovion Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.14 Koninklijke Philips N.V
      • 7.14.1 Koninklijke Philips N.V Business Overview
      • 7.14.2 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.14.3 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Product Introduction
      • 7.14.4 Koninklijke Philips N.V Response to COVID-19 and Related Developments
    • 7.15 Gerresheimer AG
      • 7.15.1 Gerresheimer AG Business Overview
      • 7.15.2 Gerresheimer AG Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.15.3 Gerresheimer AG Pulmonary Drug Delivery Devices Product Introduction
      • 7.15.4 Gerresheimer AG Response to COVID-19 and Related Developments
    • 7.16 Bespak
      • 7.16.1 Bespak Business Overview
      • 7.16.2 Bespak Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.16.3 Bespak Pulmonary Drug Delivery Devices Product Introduction
      • 7.16.4 Bespak Response to COVID-19 and Related Developments
    • 7.17 AptarGroup
      • 7.17.1 AptarGroup Business Overview
      • 7.17.2 AptarGroup Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.17.3 AptarGroup Pulmonary Drug Delivery Devices Product Introduction
      • 7.17.4 AptarGroup Response to COVID-19 and Related Developments
    • 7.18 SHL Group
      • 7.18.1 SHL Group Business Overview
      • 7.18.2 SHL Group Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.18.3 SHL Group Pulmonary Drug Delivery Devices Product Introduction
      • 7.18.4 SHL Group Response to COVID-19 and Related Developments
    • 7.19 Nypro Healthcare
      • 7.19.1 Nypro Healthcare Business Overview
      • 7.19.2 Nypro Healthcare Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.19.3 Nypro Healthcare Pulmonary Drug Delivery Devices Product Introduction
      • 7.19.4 Nypro Healthcare Response to COVID-19 and Related Developments
    • 7.20 Hovione
      • 7.20.1 Hovione Business Overview
      • 7.20.2 Hovione Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.20.3 Hovione Pulmonary Drug Delivery Devices Product Introduction
      • 7.20.4 Hovione Response to COVID-19 and Related Developments
    • 7.21 Chiesi Farmaceutici S.P.A
      • 7.21.1 Chiesi Farmaceutici S.P.A Business Overview
      • 7.21.2 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.21.3 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Product Introduction
      • 7.21.4 Chiesi Farmaceutici S.P.A Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Pulmonary Drug Delivery Devices Supply Chain Analysis
      • 8.1.1 Pulmonary Drug Delivery Devices Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Pulmonary Drug Delivery Devices Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Pulmonary Drug Delivery Devices Distribution Channels
      • 8.2.2 Covid-19 Impact on Pulmonary Drug Delivery Devices Distribution Channels
      • 8.2.3 Pulmonary Drug Delivery Devices Distributors
    • 8.3 Pulmonary Drug Delivery Devices Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Pulmonary Drug Delivery Devices, including the following market information:
      Global Pulmonary Drug Delivery Devices Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Merck, MannKind, Bristol-Myers Squibb, Mylan N.V, Omron Corp, F. Hoffmann-La Roche, 3M Healthcare, Sunovion Pharmaceuticals, Koninklijke Philips N.V, Gerresheimer AG, Bespak, AptarGroup, SHL Group, Nypro Healthcare, Hovione, Chiesi Farmaceutici S.P.A, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Dry Powder Inhaler
      Metered Dose Inhaler
      Nebulizer

      Based on the Application:
      Asthma
      COPD
      Cystic Fibrosis
      Other

      Buy now